PL1793842T3 - Leczenie zespołu zmęczenia w chorobie nowotworowej - Google Patents

Leczenie zespołu zmęczenia w chorobie nowotworowej

Info

Publication number
PL1793842T3
PL1793842T3 PL05812341T PL05812341T PL1793842T3 PL 1793842 T3 PL1793842 T3 PL 1793842T3 PL 05812341 T PL05812341 T PL 05812341T PL 05812341 T PL05812341 T PL 05812341T PL 1793842 T3 PL1793842 T3 PL 1793842T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
related fatigue
fatigue
Prior art date
Application number
PL05812341T
Other languages
English (en)
Inventor
Andrew Winokur
Arthur Jergen Prange Jr
George Gibbs Yarbrough
Original Assignee
Trh Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trh Therapeutics Llc filed Critical Trh Therapeutics Llc
Publication of PL1793842T3 publication Critical patent/PL1793842T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL05812341T 2004-09-17 2005-09-15 Leczenie zespołu zmęczenia w chorobie nowotworowej PL1793842T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US61073704P 2004-09-17 2004-09-17
US62948304P 2004-11-19 2004-11-19
US11/225,997 US7462595B2 (en) 2004-09-17 2005-09-14 Methods for treating cancer-related fatigue
PCT/US2005/032973 WO2006031980A2 (en) 2004-09-17 2005-09-15 Treatment for cancer-related fatigue
EP05812341.5A EP1793842B1 (en) 2004-09-17 2005-09-15 Treatment for cancer-related fatigue

Publications (1)

Publication Number Publication Date
PL1793842T3 true PL1793842T3 (pl) 2014-04-30

Family

ID=36060706

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05812341T PL1793842T3 (pl) 2004-09-17 2005-09-15 Leczenie zespołu zmęczenia w chorobie nowotworowej

Country Status (6)

Country Link
US (1) US7462595B2 (pl)
EP (1) EP1793842B1 (pl)
JP (1) JP2008520544A (pl)
ES (1) ES2452020T3 (pl)
PL (1) PL1793842T3 (pl)
WO (1) WO2006031980A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008297417A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of somatostatin-14 as a therapeutic agent
JP2010539064A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療への適用のための甲状腺刺激ホルモン放出ホルモン
US8597883B2 (en) 2011-02-14 2013-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for cancer-related fatigue and use thereof
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
DK3065751T3 (da) * 2013-11-08 2020-03-09 Legacy Healthcare Ltd Metode til behandling af kræft og kræftkomorbiditet

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959248A (en) 1974-04-03 1976-05-25 Merck & Co., Inc. Analogs of thyrotropin-releasing hormone
JPS51118841A (en) * 1975-04-03 1976-10-19 Takeda Chem Ind Ltd A drug for improving and treating clouding of consciousness
HU180925B (en) 1979-06-28 1983-05-30 Richter Gedeon Vegyeszet Process for producing tripeptide-amides trh-analogues,effectives on the central nerve systhem
US4426378A (en) * 1981-04-09 1984-01-17 The United States Of America As Represented By The Secretary Of The Army Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant
CA1256650A (en) 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
GB2146026A (en) * 1983-09-07 1985-04-11 Tanabe Seiyaku Co Peptides and process for preparing the same
US4719207A (en) 1984-06-25 1988-01-12 Yamanouchi Pharmaceutical Co., Ltd. CNS active substituted azetidinone compounds
IE58849B1 (en) 1984-12-18 1993-11-17 Gruenenthal Chemie Use of dipeptide derivatives for the manufacture of medicaments for the treatment of patients with amyotrophic lateral sclerosis
DE3502041A1 (de) 1985-01-23 1986-07-24 Grünenthal GmbH, 5190 Stolberg Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden
GB2171101A (en) * 1985-02-20 1986-08-20 Tanabe Seiyaku Co Peptide and processes for preparation of the same
KR960002182B1 (ko) 1987-04-08 1996-02-13 닛본 신야쿠 가부시기가이샤 향지성제
US5686420A (en) 1987-06-05 1997-11-11 Georgetown University Thyrotropin-releasing hormone analogs and method of use
JPS63316724A (ja) 1987-06-19 1988-12-26 Nippon Shinyaku Co Ltd 抗けいれん剤
US5151497A (en) 1989-02-21 1992-09-29 Japan Tobacco Inc. Histidyl peptide derivatives
DK437289D0 (da) 1989-09-04 1989-09-04 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
US5244884A (en) 1990-07-06 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Thionated analogues of thyrotropin releasing hormone
US5811512A (en) 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5526378A (en) * 1994-12-14 1996-06-11 Thomson Consumer Electronics, Inc. Blind multipath correction for digital communication channel
AU714270B2 (en) 1995-10-24 1999-12-23 Gruenenthal Gmbh Method of inhibiting sleep apnea
US6475989B1 (en) 1997-10-09 2002-11-05 Albert Sattin Use of pyroglutamyl-glutamyl-prolyl amide (EEP) for neurological and neurobehavioral disorders
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
US6815425B1 (en) 1999-10-22 2004-11-09 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical composition containing pGLU-GLU-PRO-NH2 and method for treating diseases and injuries to the brain, spinal cord and retina using same
IE20000240A1 (en) 2000-02-17 2003-03-05 Trinity College Dublin TRH-like peptide derivatives
WO2003089459A2 (en) 2002-04-19 2003-10-30 University Of Florida Thyrotropin-releasing hormone analogues and their therapeutic applications

Also Published As

Publication number Publication date
WO2006031980A3 (en) 2009-02-12
EP1793842A4 (en) 2012-12-12
EP1793842B1 (en) 2014-01-01
WO2006031980A2 (en) 2006-03-23
ES2452020T3 (es) 2014-03-31
US7462595B2 (en) 2008-12-09
JP2008520544A (ja) 2008-06-19
US20060063703A1 (en) 2006-03-23
EP1793842A2 (en) 2007-06-13

Similar Documents

Publication Publication Date Title
PL1793842T3 (pl) Leczenie zespołu zmęczenia w chorobie nowotworowej
IL178616A0 (en) Wastewater treatment
GB0515815D0 (en) Well treatment fluid
ZA200705459B (en) Treatment method
GB0412070D0 (en) Treatment device
GB0506759D0 (en) Combination treatment methods
EP1755394A4 (en) METHOD OF TREATING CANCER
GB0600692D0 (en) Well treatment
ZA200705059B (en) Cancer treatment method
EP1830847A4 (en) CANCER TREATMENT
IL179323A0 (en) Cancer treatment method
GB2430002B (en) Well treatment
GB0516068D0 (en) Well treatment
IL179359A0 (en) Cancer treatment method
EP1809276A4 (en) PROCESSING PROCESS
GB0428187D0 (en) Cancer treatment
GB0511769D0 (en) Treatment
GB0525540D0 (en) New treatment
GB0413346D0 (en) Treating cancer
GB0424663D0 (en) Sludge treatment
GB0502171D0 (en) Well treatment
EP1802617A4 (en) CANCER TREATMENT METHOD
GB0426141D0 (en) Treatment
GB0424085D0 (en) Well treatment
GB0604460D0 (en) Treatment